Skip to content
Disclosery

TAKEDA PHARMACEUTICAL CO LTD

Follow

13F filer, CIK 1395064, Tokyo, Japan

TAKEDA PHARMACEUTICAL CO LTD reported $37,950,196 across 10 holdings for the quarter ended 2024-09-30, in a 13F-HR filed 2025-02-13.

Filed (acceptance time not in the bulk data set), ingested 13F-HR 0001395064-25-000030

Period
2024-09-30
Reported value
$38M
Holdings
10
Top 10 weight
100%
New
0
Sold out
3

Largest buys vs the previous quarter

None.

Largest sells vs the previous quarter

SecurityShares changeApprox. value
DNLIexited-4,214,559-$97.9M
PHATexited-1,557,063-$16M
AMWLreduced-1,476,936-$14M
AKILI INCexited-738,819-$321K
RANIreduced-11,982-$25.9K

Ranked by the share change valued at this quarter's implied price (value over shares in the 13F). A position sold out is valued at the previous quarter's price, its last report.

Holdings, Q3 2024

Share positions as resolved from 13F-HR 0001395064-25-000030, largest first. % of portfolio is the value over $37,950,196, the sum of the share positions whose value is usable for ratios (method).

SecurityHistorySharesValue% of portfolioChangeLatest eventTimeline
HILLEVAX INCHILLEVAX INCQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2022Q4: restricted; 2023Q1: restricted; 2023Q2: restricted; 2023Q3: restricted; 2023Q4: 6,724,000 shares; 2024Q1: 6,724,000 shares; 2024Q2: 6,724,000 shares; 2024Q3: 6,724,000 shares 6,724,000$11.8M31.18%0
WVEWAVE LIFE SCIENCES LTDQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2022Q4: restricted; 2023Q1: restricted; 2023Q2: restricted; 2023Q3: restricted; 2023Q4: 1,346,892 shares; 2024Q1: 1,346,892 shares; 2024Q2: 1,346,892 shares; 2024Q3: 1,346,892 shares 1,346,892$11M29.1%0Timeline
OVIDOVID THERAPEUTICS INCQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2022Q4: restricted; 2023Q1: restricted; 2023Q2: restricted; 2023Q3: restricted; 2023Q4: 7,531,996 shares; 2024Q1: 7,531,996 shares; 2024Q2: 7,531,996 shares; 2024Q3: 7,531,996 shares 7,531,996$8.89M23.42%0Timeline
STTKSHATTUCK LABS INCQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2022Q4: restricted; 2023Q1: restricted; 2023Q2: restricted; 2023Q3: restricted; 2023Q4: 2,090,858 shares; 2024Q1: 1,501,061 shares; 2024Q2: 515,619 shares; 2024Q3: 515,619 shares 515,619$1.8M4.74%0Timeline
EQEQUILLIUM INCQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2022Q4: restricted; 2023Q1: restricted; 2023Q2: restricted; 2023Q3: restricted; 2023Q4: 1,824,977 shares; 2024Q1: 1,824,977 shares; 2024Q2: 1,824,977 shares; 2024Q3: 1,824,977 shares 1,824,977$1.51M3.99%0Timeline
XLOXilio Therapeutics Inc.Quarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2022Q4: restricted; 2023Q1: restricted; 2023Q2: restricted; 2023Q3: restricted; 2023Q4: 1,475,121 shares; 2024Q1: 1,475,121 shares; 2024Q2: 1,475,121 shares; 2024Q3: 1,475,121 shares 1,475,121$1.16M3.06%0Timeline
AMWLAMERICAN WELL CORPQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2022Q4: restricted; 2023Q1: restricted; 2023Q2: restricted; 2023Q3: restricted; 2023Q4: 1,554,669 shares; 2024Q1: 1,554,669 shares; 2024Q2: 1,554,669 shares; 2024Q3: 77,733 shares 77,733$737K1.94%-1,476,936Timeline
TURNSTONE BIOLOGICS CORPTURNSTONE BIOLOGICS CORPQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2022Q4: restricted; 2023Q1: restricted; 2023Q2: restricted; 2023Q3: restricted; 2023Q4: 895,824 shares; 2024Q1: 895,824 shares; 2024Q2: 895,824 shares; 2024Q3: 895,824 shares 895,824$499K1.31%0
RANIRANI THERAPEUTICS HLDGS INCQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2022Q4: restricted; 2023Q1: restricted; 2023Q2: restricted; 2023Q3: restricted; 2023Q4: 338,679 shares; 2024Q1: 338,679 shares; 2024Q2: 215,172 shares; 2024Q3: 203,190 shares 203,190$439K1.16%-11,982Timeline
LABSTANDARD BIOTOOLS INCQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2022Q4: restricted; 2023Q1: restricted; 2023Q2: restricted; 2023Q3: restricted; 2023Q4: 16,515 shares; 2024Q1: 16,515 shares; 2024Q2: 16,515 shares; 2024Q3: 16,515 shares 16,515$31.9K0.08%0Timeline

Sold out in Q3 2024

Positions in the previous quarter's report that this quarter's report no longer lists.

SecurityShares beforeValue beforeType
DNLIDENALI THERAPEUTICS INC4,214,559$97.9Mshares
PHATPHATHOM PHARMACEUTICALS INC1,557,063$16Mshares
AKILI INCAKILI INC738,819$321Kshares

How Q3 2024 was built

Available 13F filings of this filer for the quarter and their roles: the base report is the latest original or restatement, NEW HOLDINGS amendments filed after it are added (method).

FilingRoleAmendmentFiledAcceptedIngested
13F-HR 0001395064-25-000030 base2025-02-13acceptance time not in the bulk data set